Agios Pharmaceuticals Inc. (0HB0)
LSE
33.21
-0.68 (-2.01%)
Real-time Data
07:00 AM
Day's Range
33.2134.08
52 wk Range
22.4045.81
Financial Statements - 0HB0 - Agios Pharmaceuticals Inc.
Revenue
24.28B▲ 2.8%
Net Income
1.99B▼ 1.9%Net Margin 8.2%
EBITDA
4.65B▼ 3.4%
Free Cash Flow
2.43B▲ 21.2%
Income Statement
| Period Ending | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|
| Sales | 24.28B | 23.62B | 25.28B | 24.65B |
| Cost of Goods | 12.76B | 12.26B | 12.87B | 12.72B |
| Gross Profit | 11.52B | 11.35B | 12.40B | 11.92B |
 Operating Expense | - | - | - | - |
| Operating Income | 3.30B | 3.33B | 3.80B | 2.69B |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | 1.99B | 2.48B | 2.86B | 2.39B |
| Income Tax | 589M | 762M | 793M | 716M |
| Net Income | 1.99B | 2.03B | 2.02B | 2.44B |
| EPS Basic | 2.94 | 2.99 | 2.95 | 3.63 |
| EPS Diluted | 2.94 | 2.99 | 2.95 | 3.63 |
| Basic Shares Outstanding | 646.15M | 649.33M | 648.25M | 642.72M |
| Diluted Shares Outstanding | 646.15M | 649.33M | 648.25M | 642.72M |
| Ebit | - | - | - | - |
| Ebitda | 4.65B | 4.82B | 5.23B | 4.40B |
| Net Income Continuous Operations | 1.99B | 2.03B | 2.02B | 2.44B |
| Minority Interests | -67M | -74M | -99M | -90M |
| Preferred Stock Dividends | 26M | 15M | 14M | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
